Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tharimmune, Inc. - Common Stock
(NQ:
THAR
)
1.980
-0.010 (-0.50%)
Streaming Delayed Price
Updated: 2:40 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,475
Open
1.950
Bid (Size)
1.850 (1)
Ask (Size)
2.060 (11)
Prev. Close
1.990
Today's Range
1.940 - 2.050
52wk Range
1.835 - 142.50
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's After-Market Session
October 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 30, 2024
Via
Benzinga
Performance
YTD
-73.86%
-73.86%
1 Month
-30.77%
-30.77%
3 Month
-51.35%
-51.35%
6 Month
-63.45%
-63.45%
1 Year
-96.98%
-96.98%
More News
Read More
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
September 30, 2024
Via
ACCESSWIRE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
September 16, 2024
Via
ACCESSWIRE
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
August 12, 2024
Via
InvestorPlace
Why Tharimmune (THAR) Shares Are Moving
May 22, 2024
Via
Benzinga
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
July 22, 2024
Via
ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
July 17, 2024
Via
ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
July 16, 2024
Via
ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
July 10, 2024
Via
ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
June 20, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 17, 2024
Via
Benzinga
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 17, 2024
Via
ACCESSWIRE
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 10, 2024
Via
Benzinga
Why Tharimmune (THAR) Shares Are Getting Hammered
June 10, 2024
Via
Benzinga
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 10, 2024
Via
ACCESSWIRE
Tharimmune to Present at 2024 BIO International Convention
May 29, 2024
Via
ACCESSWIRE
Why Is Verastem (VSTM) Stock Down 62% Today?
May 24, 2024
Via
InvestorPlace
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
May 24, 2024
Via
InvestorPlace
Why Is Tharimmune (THAR) Stock Moving Today?
May 24, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 24, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 22, 2024
Via
Benzinga
Tharimmune Announces 1-for-15 Reverse Stock Split
May 22, 2024
Via
ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
May 16, 2024
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.